



















































































A  century  after  the  initial  proposition  that  the  immune  system  has  the  capacity  to 
fight against tumors, evading destruction by immune cells is now well recognized as a 
hallmark  of  cancer.  Recent  decades  have witnessed  extraordinary  improvements  in 
the use of immunotherapy against malignancies and adoptive transfer of Natural Killer 
(NK)  cells  stands  among  promising  tools  in  the  fight  against  cancer.  Clinical  studies 
have  demonstrated  the  anti‐tumor  responses  generated  by  NK  cells  both  in  the 
autologous and allogeneic settings in various cancers. Direct adoptive transfer, ex vivo 
activation and/or expansion, as well as genetic modification of NK cells aspire novel 




to  expand  polyclonal  and  highly  cytotoxic  NK  cells  showing  selective  anti‐tumor 
activity. Protocols for expansion of these cells from healthy donors and patients with 















vivo  manipulation  of  NK  cells  for  immunotherapy.  Clinical  trials  with  the  long‐term 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1 INTRODUCTION 
Immunology  as  a  scientific  discipline  is  generally  accepted  to  begin  with  Edward 
Jenner’s discovery of the smallpox vaccine in 1796. Jenner used inoculations with the 
non‐lethal cowpox virus, which also induced immunity against smallpox. Actually, the 
process  of  variolation  (deliberate  infection  with  smallpox)  was  already  in  practice 
outside Europe and was first imported into Europe around 1718 by Lady Mary Wortley 
Montagu  who  had  seen  it  being  practiced  by  physicians  in  Istanbul,  where  her 






Traditionally,  the  immune  system  is  divided  into  two  arms:  adaptive  and  innate 
immunity,  both  of  which  have  cell‐mediated  and  humoral  defense  mechanisms  to 
protect the body from foreign pathogens. Considered as the first line of defense, the 
innate  immune system is believed to precede adaptive  immunity  in the evolution of 
the  immune  system2.  Since  their  discovery,  natural  killer  (NK)  cells  have  been 
considered  characteristically  more  innate  than  adaptive  because  of  their  ability  to 





Initially  regarded  as  an  “experimental artifact”  in  T  cell  cytotoxicity  assays, NK  cells 
were first discovered in mice more than 35 years ago by Rolf Kiessling and Eva Klein, 
who  also  named  them  natural  killer  cells6,7  and  in  parallel  by  Herberman  and 







Today,  human  NK  cells  are  defined  as  CD3‐CD56+  lymphocytes.  They  comprise 




Initially  it was not clear how NK cells distinguished  target cells  they should kill  from 
those  that  they  should  spare. When Klas  Kärre  summarized  his  and  other  people’s 
work  for his doctoral  thesis, he  found a common denominator not about what was 









This  target  is  practically  invisible  to  the  NK  cell  and  no  recognition  takes  place.    (B)  The tumor  cell 
expresses ligands for  inhibitory receptors whereas it  lacks ligands for activating receptors. The NK cell 
recognizes  the  inhibitory  ligands;  therefore, no killing  takes place.  (C) The tumor cell has  significantly 
downregulated or absent expression of inhibitory ligands along with sufficient expression of activating 
ligands. Missing‐self  recognition  takes  place  and  the  target  is  killed.  (D)  The  tumor  cell  expresses 
significant levels of both inhibitory and activating ligands. The NK cells recognize both types of ligands 
and the outcome of this interaction is determined by the balance of inhibitory and activating signals. 
Human NK cells are conventionally separated  into  two subsets based on  their CD56 
expression.  This  separation  is  not  just  phenotypic  but  rather  has  many  functional 





exclusively  express  the  IL‐2  receptor  α  chain  (IL‐2Rα  or  CD25)  while  they  lack  or 
express  only  at  very  low  levels  the  FCγRIII  (CD16).  On  the  other  hand,  the  CD56
dim 
subset  has  high  expression  of  CD16  and  lacks  CD25  expression.  These  properties 
assign very different roles to the different subsets with regards to antibody dependent 
cellular  cytotoxicity  (ADCC)  and  response  to  IL‐2  stimulation.  In  addition  to  distinct 
expression of adhesion molecules and cytokine receptors, CD56bright NK cells have the 
capacity  to  produce  high  levels  of  immunoregulatory  cytokines,  but  have  low‐level 
expression of killer‐cell immunoglobulin‐like receptors (KIRs) and are poorly cytotoxic. 




the  immune  system.  Thus,  studies  of  the biology  of  human NK  cells  are  eventually 
approaching  NK  cells  as  separate  CD56bright  and  CD56dim  subsets  rather  than  a 
homogenous population. 
As  the  name  implies,  NK  cells  can  kill without  prior  sensitization,  but  they  are  also 
potent  producers  of  various  cytokines,  including  IFN‐γ,  TNF‐α,  GM‐CSF  and  IL‐320. 




and  B  cells  through  IFN‐γ  production21. Moreover,  depletion  of  NK  cells  in  C57Bl/6 
mice leads to increased engraftment of neuroblastoma (NB) xenografts mainly due to 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1.2 NK CELL RECEPTORS 
NK  cell  cytotoxicity  is  partially  the  result  of  a  complex  interaction  between  the 
inhibitory and activating signals coming from surface receptors28. Table 1 provides a 
selection of human NK cell activating and inhibitory receptors identified so far. Upon 
recognition of  the  ligands on  the  target  cell  surface by  activating NK  cell  receptors, 




CD  Alternative name  Type of signal  Ligand  Distribution on NK cells 
CD2  LFA‐2  Activation  CD58 (LFA‐3)  All 
CD7  LEU‐9  Activation  SECTM1, Galectin  All 
CD11a  LFA‐1  Activation  ICAM‐1,‐2,‐3,‐4,‐5  All 
CD11b  Mac‐1  Activation  ICAM‐1, Fibrinogen  All 
CD16  FcγRIII  Activation  IgG  Mainly CD56dim 
CD44  Hyalunorate receptor  Activation  Hyalouronan  All 
CD59  Protectin  Activation  C8, C9  All 
CD69  CLEC2C  Activation  Unknown  Activated 
CD85j  ILT‐2 (LIR‐1)  Inhibition  HLA‐A, ‐B, ‐G  Subset 
CD94/CD159a  CD94/NKG2A  Inhibition  HLA‐E  Most 
CD94/CD159c  CD94/NKG2C  Activation  HLA‐E  Most  
CD96  TACTILE  Activation  CD155  Activated, Low on resting 
CD160  BY55  Activation  HLA‐C  All 
CD161  NKR‐P1  Activation/Inhibition  LLT1  Subset  
CD223  Lag3  Activation  HLA Class II  Activated 
CD226  DNAM‐1  Activation  CD112, CD155  All  
CD244  2B4  Activation/Inhibition  CD48  All 
CD305  LAIR‐1  Inhibition  Collagen  All 
CD314  NKG2D  Activation  MICA, MICB, ULB1‐4  All 
CD319  CRACC  Activation  CRACC  Mature NK cells 
CD328  Siglec‐7  Inhibition  Sialic acid  All 
CD329  Siglec‐9  Inhibition  Sialic acid  Subsets 
CD335  NKp46  Activation  Viral hemagglutinins  All 
CD336  NKp44  Activation  Viral hemagglutinins  Activated 
CD337  NKp30  Activation  Viral hemagglutinins  All 
Various  KIR2DS, KIR3DS  Activation  HLA Class I  Subsets 
Various  KIR2DL, KIR3DL  Inhibition  HLA Class I  Subsets 
‐  NKp65  Activation  KACL  Most 
‐  NKp80  Activation  AICL  All 
‐  NTB‐A  Activation  NTB‐A  All 
‐  KLRG1  Inhibition  E‐,N‐,P‐cadherin  All 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However,  these  processes  are  tightly  controlled  by  a  group  of  inhibitory  receptors. 
These receptors act as negative regulators of NK cytotoxicity and inhibit the action of 





type  I  (extracellular amino  terminus) membrane proteins  that contain either  two or 
three extracellular Ig‐like domains32 and are designated KIR2D or KIR3D, respectively. 
The  cytoplasmic  domains  of  the  KIRs  can  be  either  short  (S)  or  long  (L),  roughly 
corresponding  to  their  function  as  either  activating  or  inhibitory  receptors 
respectively. Members  of  the  KIR  family  recognize  HLA‐A,  HLA‐B  and HLA‐C  alleles, 
and KIR2DL4 recognizes HLA‐G33. The KIRs are clonally distributed on NK cells, which 
ensures  that even  the  loss of a  single HLA allele  (a common event  in tumorigenesis 
and viral infections) can be detected by a pool of NK cells33,34.  
The  activating  side  of  the  balance  also  includes  a  series  of  different  receptors.  The 
main activating receptor group is the natural cytotoxicity receptors (NCRs)29 and it  is 
believed  that  the main  control  over  the NK  cell  activating pathways  is  regulated by 
these receptors. Currently there are three different NCRs identified: NKp3035, NKp4436 
and NKp4637. NKp30 and NKp46 are expressed both in activated and non‐activated NK 
cells  whereas  NKp44  expression  is  restricted  to  activated  NK  cells.  Most  activating 
receptors do not directly  signal  through  their  cytoplasmic  tail,  but  instead associate 
non‐covalently  with  other  molecules  containing  immunoreceptor  tyrosine‐based 
activation  motifs  (ITAM)  that  serve  as  the  signal  transducing  proteins.  NKp30  and 
NKp46  are  couples  with  CD3ζ  whereas  NKp44  is  coupled  with  DAP12.  NK  cell 
activation has been studied extensively in recent years and is discussed elsewhere38,39. 
NK cells have been described as large granular 
lymphocytes  and  their  granularity  is  their 
means  for  target  cell  killing  (Figure  2).  These 
granules  contain  perforin  and  granzyme  B40 
and  both  are  postulated  to  bind  the  target 
surface  as  part  of  a  single  macromolecular 
complex41.  
Figure  2.  Mechanisms  of  NK  cell  cytotoxicity.  The 
cytotoxicity  of  NK  cells  is  carried  out  by  two  main 
mechanisms. The  first mechanism  is granule‐dependent 
cytotoxicity  (A)  where  upon  triggering  by  activating 
receptors  or  the  Fc  receptor  (CD16),  the  cytotoxic 
granules  in  the  cytosol  of  the  NK  cell  are  polarized 
towards  the  immunological  synapse  and  the  contents 
(mainly  perforin  and  granzyme  B)  are  unleashed  upon 
the  target  cell  by  exocytosis.  The  second mechanism  is 
the triggering of apoptosis pathways in the target cell via 
stimulation  of  death  receptors  (B)  on  the  target  cell 
surface by TRAIL or Fas  ligand expressed on the NK cell 
surface as well as secretion of TNF‐α. 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When  an  NK  cell  is  killing  a  target  cell,  perforin  and  granzyme  B  are  released; 
granzyme  enters  the  target  cell  and  mediates  apoptosis  while  perforin  disrupts 
endosomal  trafficking42,43. NK cells  can also express FasL and TNF‐related apoptosis‐
inducing  ligand  (TRAIL), which  are  both members  of  the  TNF  family  and  have  been 




strategy  to  target  NK  cells  to  tumors  specifically  is  by  making  use  of  their  ADCC 
capabilities in vivo. ADCC by NK cells is mediated through binding of immunoglobulin 
complexes  or  antibody‐coated  targets  to  the  Fc  receptor  CD16.  Antigen  density, 
structure,  and  specificity  of  Fc  binding  are  the  critical  components  for  efficient 
induction of ADCC47. Several  isotypes of murine monoclonal antibodies (IgG1,  IgG2a, 
IgG2b, IgG3)48,49 have also been shown to trigger ADCC in NK cells. A comprehensive 

















The  expression  of  FasL  by  tumor  cells  as  a  counterattack  strategy  against  immune 
effectors such as T cells and NK cells  is also common55‐57. Additionally,  the defective 
expression of  activating  receptors  and  various  intracellular signaling molecules  by  T 
cells and NK cells in cancer patients has been observed and reported to correlate with 
disease  progression58.  It  has  also  been  shown  that  malignant  cells  secrete 
immunosuppressive factors that inhibit T and NK cell proliferation and function59,60.  
Studies  on  patients  with  AML  have  convincingly  demonstrated  the  existence  of  an 
NCRdull phenotype in NK cells and more interestingly that the in vitro co‐culture of NK 
cells  and  tumor  cells  also  result  in  the  induction  of  this  defective  phenotype61. 






























early  stages.  The  main  clinical  symptoms  of  the  disease  are  related  to  the 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accumulation of malignant plasma cells, followed eventually by bone destruction and 
subsequent  hypercalcemia,  bone  marrow  failure,  anemia,  renal  failure  and  an 
increased  risk  of  infection  due  to  immune  failure.  Patients  primarily  present  with 
serious  bone  pain  and  fatigue  related  to  anemia  as  well  as  recurrent  infectious 
disease.  The occurrence of  a monoclonal  immunoglobulin  (M‐component)  in  serum 
and  light  Ig  chains  in  the  urine,  resulting  from  the  sustained  Ig  production  of  the 
malignant  plasma  cells,  is  an  important  diagnostic  tool.  MM  accounts  for 
approximately  2% of  all  cancer  deaths  and  20% of  deaths  caused  by hematological 
malignancies97.  Factors  that predict  survival  in MM such as β2‐microglobulin  (β2M), 
creatinine and hemoglobin  (Hb)  levels have been well‐defined98,99. Furthermore,  the 
occurrence  of  various  chromosomal  abnormalities  among  the  malignant  cells  have 
been shown to have an impact on prognosis100‐102. The incidence of MM in Europe is 
4.5‐6.0/100  000/year  with  a median  age  at  diagnosis  of  between  63  and  70  years 
while the mortality is 4.1/100 000/year103,104. 
The level of cyclin D1, D2 or D3 expression in all MM cells is significantly higher than in 
normal  BM  plasma  cells105.  This  makes  the  myeloma  cells  more  sensitive  to 
proliferative  stimuli  from  the  BM  microenvironment106  resulting  in  selective 
proliferation of tumor cells that produce osteolytic factors including RANK ligand and 
large  amounts  of  MIP‐1α  as  well  as  immunosuppressive  factors  such  as  IL‐10. 
Approximately  70%  of  MM  patients  have  elevated  levels  of  MIP‐1α  in  their  BM 
plasma107 which  directly  stimulates  osteoclast  (OCL)  precursors  to  differentiate  into 
bone  resorbing  OCL108,109,  resulting  in  elevated  rate  of  bone  destruction.  Also, 
adhesive interactions between myeloma cells and BM stromal cells  induce increased 
production  of  RANKL  and  IL‐6  by  stromal  cells  and  in  this  way  increase  OCL 
formation110. Besides, MM cells have also been shown to produce DKK1 that inhibits 
the WNT pathway which is critical for osteoblast differentiation111. Altogether, these 
changes  in  the BM microenvironment  lead  to  the development of a  tumor  that will 
cause irreversible damage to bones and induce formation of osteolytic lesions. 
Allogeneic  stem  cell  transplantation112,113  might  be  curative  for  a  small  group  of 
eligible  patients,  but  the  common  treatment  of  choice  for  patients  under  60  –  65 
years of  age has been high‐dose  chemotherapy  (HDT)  followed by autologous  stem 
cell transplantation (ASCT)114. Although ASCT is still considered a golden standard for 
treatment  of  MM  patients  younger  than  65  years  of  age,  mainly  based  on  two 
prospective trials 115,116, some doubt remains about which  induction regimen should 
be used, whether single or tandem ASCT should be employed and whether melphalan 
should  be  used  alone  or  in  combination  with  other  drugs  as  high  dose  treatment 
(HDT) 117. Yet, approximately only one‐third of all patients with MM live longer than 5 
years. On  the other  hand,  recent  years  have witnessed  a  significant  increase  in  the 
survival  rates  for  MM  patients  due  to  the  introduction  of  combination  therapies 
including  proteasome  inhibitors  such  as  bortezomib  and  immunomodulatory  drugs 
(IMiDs) such as thalidomide, and lenalidomide118.  
Despite  the  rapid  development  of  new  agents,  MM  continues  to  be  an  incurable 
disease with a fatal outcome in the majority of patients, especially those in advanced 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stages.  Thus,  novel  therapeutic  modalities  such  as  immunotherapy  warrant 
exploration  in  an  attempt  to  increase  life  expectancy119.  Yet,  the  impaired  immune 
system in MM patients  is evident  in their well‐recognized susceptibility to  infectious 
complications120. Previous reports have convincingly demonstrated that while NK cells 
are  functional  in  MGUS  (monoclonal  gammopathy  of  undetermined  significance,  a 
premalignant condition resembling MM), and to some extent in early stages of MM, 
further  progression  of  the  disease  is  accompanied  by  a  serious  decline  in  NK  cell 
function121‐125.  In  the  autologous  setting,  this  marked  NK  cell  defects  must  be 
overcome for successful  induction of an anti‐MM response by the patient’s own NK 
cells.  
Recent evidence  suggests  that  the underlying dysfunction of  the  immune  system  in 
MM  patients  originate,  at  least  in  part,  from  dendritic  cells126  or  regulatory  T 
cells127,128.  Moreover,  the  secretion  of  TGF‐beta,  IL‐10,  IL‐6  and  prostaglandin  E2 
(PGE2)  by  the  tumor  microenvironment  negatively  affects  NK  cell  function  while 
activation  of  signaling  molecules  such  as  STAT3  promotes  MM  cell  growth  and 
suppresses  NK  cell  function129‐131.  Expression  of  the  IL‐15  receptor  and  autocrine 
stimulation  of  MM  cells  by  IL‐15  production  can  also  be  considered  as  a  factor 
negatively  affecting NK  cells  since  this might  result  in  the sequestration  of  IL‐15  by 
MM  cells  which  would  otherwise  be  used  for  NK  cell  survival  and  activation132. 





explained  by  impaired  NK  cytotoxicity124,141  and  increased  levels  of  soluble  IL‐2 
receptors142  in MM patients as well  as decreased expression of activating receptors 
compared  to  those  in  healthy  controls84.  Moreover,  the  high‐dose  secretion  of M‐
component may also directly effect NK cell cytotoxicity80,141,143,144. MM cells have also 
been  shown  to  express  programmed  death  receptor  ligand‐1  (PD‐L1)  which  upon 
interaction  with  the  programmed  death  receptor‐1  (PD‐1)  on  NK  or  T  cells,  may 
suppress adaptive and innate immune responses against MM145,146.  





due  to  the  lack  of  knowledge  on  the  cellular  and molecular  details  of  the  immune 
system,  half  a  century  later,  Thomas  and  Burnet  put  forward  the  “cancer 
immunosurveillance” theory148. While this theory was seriously challenged in the first 
years,  it has stood the test of  time and been validated,  reaffirming the  feasibility of 




Figure  3  presents  an  overview  of  current  and  future  approaches  to  NK  cell‐based 
immunotherapeutic  strategies  in  the  treatment  of  cancer.  A  critical  prerequisite  for 
efficient NK cell‐based immunotherapy seems to be the reduction of the tumor mass 
by surgical removal, chemotherapy or radiotherapy in order to give the effector cells a 
numerical  advantage.  The  yellow  shaded  upper  left  panel  represents  the  in  vivo 
modulation of NK cell activity against tumor via (A) stimulation with cytokines and/or 
(B)  infusion  of  tumor‐
specific  monoclonal 
antibodies  in  order  to 
trigger an ADCC response. 
The  green  shaded  lower 






Autologous  or  donor  NK 
cells  can  be  transferred 
after (C & H) ex vivo short‐
term  activation,  (D  &  G) 
ex  vivo  long‐term 
activation  and  expansion 
or  (E  &  F)  genetic 
modification.  Infusion  of 
(I)  purified  unstimulated 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1.4.1 Modulation of endogenous NK cell activity 
1.4.1.1 IL‐2 alone 
The  cDNA encoding  the human  IL‐2  gene was  cloned  in 1983151  after  a  long  search 
starting  in 1965  for  the  soluble  factors  in  lymphocyte conditioned media  that  could 
sustain the proliferation of T cells in culture152,153. It is now well known that IL‐2 affects 
many  types of cells  in  the  immune system  including cytotoxic T cells, helper T cells, 
regulatory T cells, B cells and NK cells. Currently, there are three distinct chains of the 
IL‐2 receptor identified; the α (CD25), β (CD122) and γ (CD132) chains. The γ chain is 
shared  among  various  cytokine  receptors  (IL‐4,  IL‐7,  IL‐9,  IL‐13,  IL‐15,  IL‐21),  thus 
named  the  common γ  chain  and  it  is  essential  for  lymphoid  development154.  The β 
chain  is  shared  between  IL‐2  and  IL‐15  receptors155,156.  The  β  and  γ  chains  come 
together to form the  intermediate affinity  IL‐2/15 receptor. The distinction between 
the high affinity receptors for IL‐2 and IL‐15 comes with the α chains. The IL‐2Rα chain 
alone  is  regarded as the  low affinity receptor and  is believed to  lack the capacity to 
deliver  intracellular signals due to  its short  intracellular tail157. However, when the α 
chain  forms  a  complex  with  the  β  and  γ  chains,  the  high  affinity  IL‐2  receptor  is 
formed.  The  co‐expression  of  all  three  chains  is  confined  to  regulatory  T  cells, 
CD56bright  NK  cells  as well  as  activated  conventional  CD4+  and  CD8+  T  cells158.  Thus, 
these cells are expected to give a better response to the presence low dose IL‐2. 
It has been well defined that IL‐2 activation of NK cells can result in cytotoxic activity 
against  targets  that  were  previously  NK‐resistant159‐161.  Early  reports  of  IL‐2  based 
treatment on animal models have established a  solid basis  for  the efficiency of  this 
approach  for  cancer  immunotherapy  in  many  different  settings162‐170.  Although 
cytotoxic T cells have been the primary point of  interest, especially during  the early 
phases  of  IL‐2  use,  the  antitumor  response  triggered  by  IL‐2  were  frequently 
attributable  to NK  cells171‐175.  Likewise,  our  group  has  demonstrated  in  a  syngeneic 
murine model of MM that NK cells are the primary mediators of IL‐2 induced tumor 
rejection175. 
In  the  clinical  setting,  the  pioneering  works  of  Rosenberg  et  al.176,177,  which  have 








attempt  to  promote  in  vivo  killing  of  tumor  cells  have  been  used  by  many 
investigators. 
IL‐2 has  received FDA approval  for  the  treatment of metastatic  renal cell  carcinoma 
(RCC) in 1992 based on its ability to induce an objective response rate of 15‐20%181. It 
has  also  been  demonstrated  in  RCC  patients  undergoing  IL‐2  based  therapy  and 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nephrectomy,  that  a  higher  percentage  of  circulating  NK  cells  is  a  predictor  of 
response182. 
The use of  IL‐2 alone has been attempted  in many other tumor  types, mostly as an 
adjuvant  to  chemotherapy or  stem cell  transplantation  (SCT). Treatment of patients 
with  breast  cancer  and  lymphoma  using  IL‐2  was  shown  to  significantly  increase 
number of circulating NK cells and their cytotoxicity against NK resistant breast cancer 
and  lymphoma  cell  lines183.  Many  other  similar  studies  on  immunostimulation  in 
cancer  patients  have  made  similar  observations  where  IL‐2  infusions  induce  an 
increase in white blood cell counts, increase in circulating T cells and mostly CD56bright 
NK cells, elevated cytotoxic activity of NK cells184‐186. Yet, such studies have primarily 





have an effective  cytotoxic  activity  against MM cell  lines  and tumor  cells  from MM 
patients136. Our group has demonstrated (PAPER I) that NK cells from MM patients can 
be expanded ex vivo using GMP‐compliant components, and they show high cytotoxic 
activity  against  autologous MM  cells  while  retaining  their  tolerance  against  normal 
cells of the patient188. Other researchers have also shown that HLA Class I molecules, 
NCRs  and NKG2D  take  part  in  the  recognition  of myeloma  cells  by  autologous  and 
allogeneic NK cells85,137. Likewise, NK cells  from AML patients in remission have also 
been  expanded  ex  vivo  and  showed  cytotoxic  activity  against  allogeneic  and 
autologous AML blasts, which could be further enhanced by IL‐2189.  In a clinical AML 
study,  where  IL‐2  was  used  alone  as  14‐day  cycles  of  low‐dose  IL‐2,  for  in  vivo 
expansion of NK cells, followed by 3 day higher doses aimed to induce cytotoxicity of 
in vivo expanded NK cells, no prolongation of disease‐free or overall survival was seen 
and the authors concluded that  low‐dose  IL‐2 maintenance  immunotherapy alone  is 
not a successful strategy to treat older AML patients190.  




As mentioned  above, within  the NK  cell  population,  the  IL‐2Rα  (CD25)  that  confers 
high  affinity  for  IL‐2  is  uniquely  expressed by CD56bright  cells191, which  could  explain 
their selective expansion in response to low‐dose IL‐2. Likewise, the in vivo expansion 
of  another  CD25  expressing  regulatory  cell  subset;  Treg  cells  could  also  overwhelm 
and/or suppress the antitumor activity.  The potential of Treg cells to dampen NK cell‐
mediated  antitumor  responses  has  primarily  been  suggested  in  a murine  leukemia 
model192.  The  effect  of  Treg  cells  in  cancer  immunotherapy  has  now  been  better 
recognized193,194  and  attempts  to  circumvent  such  suppression  are  underway195. 
Moreover,  recent advances  in  the engineering of novel cytokines based on  IL‐2  that 















However,  the  IL‐15Rα  chain  has  been  shown  to  signal  independently  from  the  β/γ 
heterodimer, which in part explains the different effects of the two cytokines202,203. . 
IL‐12  differs  from  these  two  cytokines  due  to  the  fact  that  IL‐12  receptor  lacks  the 
common γ  chain.  The  IL‐12  receptor  is  composed of  two  subunits:  IL‐12Rβ1 and  IL‐
12Rβ2204,205.  Studies  have  shown  that  IL‐2  activated  PBMCs  displayed  increased 
cytotoxic activity against autologous primary lung cancer cells, which could be further 
augmented with  the  addition of  IL‐12206.  This may be  explained by  the observation 
that  IL‐2  upregulates  the  expression  of  IL‐12Rβ1  and  IL‐12Rβ2207.  The  increased 
expression of  IL‐12R on NK cells  in patients treated with  low dose IL‐2 also confirms 
this explanation207. NK cells have been shown to kill NB cell lines when activated with 




receptor  can  activate  the  different  downstream  targets211‐213.  IL‐21  alone  promotes 
functional maturation214  and  survival  of  NK  cells  but  does  not  induce  proliferation, 
while it synergizes with IL‐2 and IL‐15 for induction of NK cell expansion in vitro215 and 
modulation  of  surface  receptor  expression  such  as  upregulation  of  NKG2A,  CD25, 









tumors  induce  dysfunction  or  tolerance  of  local  immune  cells63.    The 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immunosuppressive effect of reactive oxygen species (ROS) derived from tumor cells, 
tumor‐associated macrophages, or monocytes activated by cytokine therapy has been 




have  tried  combination  of  IL‐2  with  histamine,  an  inhibitor  of  ROS  synthesis  in 
monocytes/macrophages228,  in  order  to  counteract  the  negative  effect  of  ROS 
originating  mainly  from  the  expanding  monocyte/macrophage  population.  In  a 
randomized phase II trial where 63 patients with metastatic RCC were treated with IL‐
2  and  histamine229,  addition  of  histamine  resulted  in  a  decrease  of  monocyte 
expansion  and  number  of  intratumoral  macrophages  as  well  as  an  increase  in  the 
number  of  tumor‐infiltrating  NK  cells  and  CD8+  T  cells.  The  same  study  also 
demonstrated  a  likely  correlation  between  the  number  of  circulating  NK  cells  and 
cytotoxicity.  Likewise,  histamine  has  also  been  shown  to  synergize with  IL‐2230  and 
reverse  the  inhibition  of  NK  cell  cytotoxicity  against  heterologous  AML  blasts  by 
myeloid‐derived ROS231. Hellstrand et al. have reported treatment of 22 AML patients 
(mean age 59) with IL‐2 and histamine. The treatment was well tolerated and showed 
an  impressive  survival  benefit232,  which  stands  out  as  a  promising  finding  to 
counterweigh the ineffectiveness of IL‐2 treatment in certain settings. A more recent 
report of a phase  III  trial with  this approach  including 320 patients has convincingly 
shown that the use of IL‐2 along with histamine significantly improves leukemia‐free‐
survival  of  AML  patients  in  remission  by  reducing  the  risk  of  relapse233,234  and  the 
treatment has now been approved in EU for AML patients in first CR.  
Other investigators have combined the use of IL‐2 and IFN‐α in the clinical setting. It 
has  been  demonstrated  that  perioperative  treatment  with  IFN‐α  significantly 
increases NK cell activity although the number of cells are decreased235. Atzpodien et 
al. infused IL‐2 along with interferon‐α to 47 patients with various malignancies. They 
have  observed  a  significant  relation  between  the  increase  of  circulating  NK  cell 
numbers (CD56+) and the response236. Molto et al. have observed in 8 metastatic RCC 





In  a  similar  study,  low‐dose  IL‐2  for  5  days  per week  and  IFN‐α  twice weekly  for  4 
consecutive weeks was applied to 27 patients with advanced renal cell carcinoma. A 




and  tumor  biopsies  from  13  patients  with  metastatic  malignant  melanoma  were 
followed and a trend towards a gradual increase in the absolute number of circulating 
NK cells in patients maintaining stable disease during the therapy was observed. The 













protocols  to  deplete  CD4+/CD8+  αβT  cells  are  possible  and  result  in  passive 
enrichment  of  innate  lymphocytes  such  as  NK  cells  and  γδT  cells  which  seem  to 
preserve their proliferative and cytotoxic capacity241.  Simple purification of NK cells by 
a single‐step or 2‐step procedure may be enough for most applications. Leung et al.242 
have  demonstrated  that  donor  NK  cells,  purified  by  a  clinical‐scale  two‐step 
immunomagnetic separation method, had normal expression of cell surface markers, 







































4  99  42  >90  NR  NR  NR 








11  95  33  95  0.01  5  NR 
Frohn248  SuperMACS NK cell selection  10  85  50  NR  1  8.5  0.3 
The actual obstacle in clinical studies with adoptive transfer of NK cells originates from 
the  fact  they  are  normally  present  only  in  low numbers  in  PBMCs  and  effector  cell 
preparations such as lymphokine activated killer (LAK) cells. Obtaining a large number 
of  NK  cells  is  an  influential  albeit  difficult  task  that  underlies  the  most  significant 
challenge for the development of successful NK cell adoptive transfer protocols. Thus, 
many  researchers have worked on  the expansion of NK cells. Table 4  summarizes a 
selection  of  studies  reporting  successful ex  vivo  expansion  of  NK  cells  for  adoptive 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Our  group  has  previously  described  a  novel  method  comprising  GMP‐compliant 
components  that  facilitates expansion of high numbers of polyclonal NK cells  in cell 
culture flasks using PBMCs from healthy donors 254, as well as patients with B‐CLL 256 
and  MM188  (PAPER  I).  These  cells  were  shown  to  exert  specific  cytotoxic  activity 
against  fresh  human  tumor  cells  in  vitro  188  and  in  experimental models  of  human 
tumors  262  which  opens  up  the  possibility  to  be  evaluated  in  clinical  settings.  
Concurrently,  we  have  successfully  completed  the  safety  evaluation  of  this  cell 






yields  expanded  cells  with  similar  phenotype.  Factors  such  as  distribution  of  KIR 
expressing  populations  and  expression  of  other  activating  and  inhibitory  receptors 
may  be  of  importance  and  need  to  be  checked  thoroughly.  The  level  of  CD16 
expression  in  the  final  product  should  also  be  optimized  in  order  to make way  for 
possible  future  use  of  expanded  NK  cells  along  with  tumor‐targeting  antibody 
infusions.  Keeping  in  mind  that  such  differences  in  NK  cell  phenotype  due  to  the 
expansion method used might have a significant effect on the clinical applicability and 
efficiency, the ultimate answers lie in testing these cells in clinical trials. Such clinical 





in  a  syngeneic  immunocompetent  mouse  model175.  Additionally,  it  has  also  been 
demonstrated  that  activated  NK  cells  from  AML  patients  are  cytotoxic  against 
autologous  AML  blasts  in  vivo  in  a  NOD/SCID  model265.  Supported  by  the 





clinical  benefit  with  long‐term  ex  vivo  activated  NK  cells.  Corroborating  this 
hypothesis, we have observed that long‐term expansion and activation of autologous 
NK  cells  from  MM  patients  provide  significantly  superior  cytotoxic  activity  against 
autologous tumor cells when compared to short‐term activated autologous NK cells188 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1.4.2.3 Adoptive transfer of allogeneic NK cells 
The use of allogeneic NK cells is tentatively alluring, given the current comprehensions 
of NK  cell  regulation.  A  provisional  prerequisite  for NK  cell  alloreactivity  is  that  the 
recipient lacks one or more KIR ligands present in the donor. The donor may in such 
situations  have NK  cells  that  express  inhibitory  KIR  for which  there  is  no  ligand  on 
recipient  cells.  Therefore,  a  KIR  ligand‐mismatched  donor  is  likely  to  give  the  best 
chances  for  clinical  response270‐272.  In  certain donor‐recipient combinations,  chances 
for missing‐self  may  prevail,  providing  better  possibilities  for  anti‐tumor  reactivity. 
Within  the  setting  of  NK  cell‐based  immunotherapy,  the  KIR‐ligand  mismatch 
phenomenon has attracted great attention273 after the ground‐breaking retrospective 
analysis of haplotype mismatched hematopoietic stem cell  transplants by Ruggeri et 




different  prospective  studies  have  suggested  that  development  of  NK  cells  after 
haploidentical  transplantation  is  hampered  and  these  cells  have  phenotypic  and 
functional deficiencies275,276. Table 6 presents a selection of clinical trials with infusion 
of allogeneic NK cells244,272,277‐285. 
In  an  interesting  recent  study by  Shi et  al.  10 patients with MM were  treated with 
haploidentical NK cells before ASCT. The allogeneic NK cells persisted in the periphery 
of the patient reaching a maximum at around 7 days and eventually fading away until 
they  were  undetectable  by  day  14.  The  increasing  donor  chimerism  up  to  day  7 
suggests  a  confirmation  for  Miller  et  al.’s  observation  of  in  vivo  expansion. 
Encouragingly,  a  complete  remission  rate  of  50%  was  reported.  Although  the 
allogeneic NK cells were not detectable after day 14, the efficiency of this approach 
may  suggest  that  even  without  long‐term  engraftment,  a  clinical  benefit  for  the 
patients can be observed. This brings the question about the in vivo fate of adoptively 
transferred allogeneic NK cells. Brand et al. conducted a study where the allogeneic 




short  initial uptake  in the  lungs. A total of 2/4 evaluable metastases showed a clear 
accumulation of transfused NK cells286. 





















































































































































































































































































































































































































































































































































































































of a  functional gene  into the cell,  in cases where the cellular copies of the gene are 
non‐functional due to mutations, causing what is called a monogenic disorder. In such 
cases,  introduction  of  a  healthy  copy  of  the  gene  is  expected  to  result  in  the 
expression of a functional protein and compensate for the loss of function caused by 
the mutations. The revolutionary idea here is to treat disease by the administration of 
genetic  material,  which  will  produce  the  necessary  amount  of  protein  in  order  to 
correct  the condition. Therefore,  instead of  treating  symptoms or  replacing  the  lost 




After  initial  propositions295  and  early  clinical  investigations  of  gene  transfer  into 
human cells296, on September 14, 1990, Ashanti DeSilva, a four‐year old patient with 
adenosine  deaminase  deficiency  became  the  first  person  in  history  to  receive  gene 
therapy297  at  a  first‐in‐man  trial  by Blaese et al.  Positive  results  from  this  trial  have 
paved the way for many other gene therapy clinical trials to come, all with their ups 
and  downs.  In  this  seminal  paper297,  the  authors  conclude:  “Although  many 
components remain to be perfected, it is concluded here that gene therapy can be a 
safe  and  effective  addition  to  treatment  for  some  patients  with  this  severe 
immunodeficiency disease.” While the field still is busy with fulfilling the prophecy of 
perfecting  the  many  components,  recent  years  have  witnessed  extraordinary 
developments along with  failures and success stories coming one after  the other298. 
Besides clinical applications, gene delivery has developed  into a standard  laboratory 
technique  driving  discoveries  in  basic  research  from  analysis  of  gene  function  by 
plasmid  DNA  transfection  all  the way  to  development  of  induced  pluripotent  stem 
cells (iPSCs)299,300 using viral delivery mechanisms. 
Even from the very early days, the possibility of gene transfer into a cell has surpassed 
the  boundaries  of  the  classical  definition  of  gene  therapy  that  relies  on  correcting 
defective gene expression. As with the gene‐marking study by Rosenberg et al.296, ex 
vivo  introduction of  foreign  genes to  the adoptively  transferred hematopoietic  cells 
were  primarily  used  to  track  genetically  modified  cells  in  vivo301.  Especially  in  the 
immunotherapy  field,  this has sparked the  interest  in genetically modifying  immune 
effector cells in order to use them as microscopic soldiers that could seek and destroy 
the malignant cells inside the body302,303. Traditionally, the focus has been on T cells, 









techniques  for  the  in  vitro  manipulation  of  DNA  have  developed,  the  possibility  of 
using viruses as gene delivery mechanisms have surfaced. After the initial discovery of 
gene transduction into E.coli by bacteriophage λ304, in 1968, Rogers and Pfuderer have 




The  problem  with  viruses  is  that  they  are  generally  pathogenic  and  immunogenic. 
Therefore,  other  researchers  have  ventured  upon  the  use  of  non‐viral  delivery 
methods.  Since  the  spontaneous  uptake  of  nucleic  acids  by  cells  is  very  limited, 
methods  of  non‐viral  gene  delivery  rely  upon  coupling  of DNA  to  carrier molecules 





is  generally  done  by  using  carrier  molecules  that  help  DNA  condensation  and 
protection  from  nucleases  as  well  as  the  use  of  hydrophilic  moieties  for  steric 
stabilization  and  surface  charge  shielding.  Common  examples  include  the  use  of 
protamine305, lipids306‐308, gelatin309 and PEGylation306,307,309‐313. Secondly, the crossing 
of  the  cellular  lipid  bilayer  membrane  presents  a  major  barrier.  Here,  general 
mechanisms include targeting a ligand on the cell surface that could trigger receptor‐
mediated  endocytosis  such  as  transferrin  receptor306,313,  EGF310,  antibodies305,307, 
RGD312,  etc.  Once  the  nucleic  acids  are  taken  up,  disruption  of  the  endosome  and 
subsequent  transfer  into  the  nucleus  also  needs  to  be  assured.  Agents  such  as 
PEI310,312, and DOPE306 as well as nuclear  localization signals from various viruses are 
commonly used  for  these processes.  It  is quite often  that  the designers of non‐viral 
vectors  borrow  ideas  and  components  from  viruses  that  have  been  perfected  by 
millions of years of evolution. Non‐viral vectors are further reviewed in the following 
citations314,315. 
Contrary  to  non‐viral  vectors,  viral  delivery  of  genes  is  generally  highly  efficient. 
However, using viruses for gene delivery has problems of its own. In order to get rid of 
the  pathogenicity  of  the  virus  and  ensure  that  the  virus will  not  be  replicating  and 
spreading, all viral genes and sequences except those necessary for packaging of the 
viral  genome  are  removed.  This  also  opens  up  space  inside  the  viral  genome  for 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therapeutic  genes  to  be  inserted. Moreover,  it  is  common  practice  to  change  viral 
promoter  elements  and  envelope  proteins  for  enhancing  safety  and  ensuring  the 







Lentivirus  Adenovirus  AAV  Herpes virus 
Vaccinia 
virus 
Family  Retroviridae  Retroviridae  Adenoviridae  Parvoviridae  Herpesviridae  Poxviridae 
Genome 
type 
ssRNA (+)  ssRNA (+)  dsDNA  ssDNA  dsDNA  dsDNA 
Genome 
size 
9 kb  9 kb  39 kb  5 kb  120‐200 kb  130‐280 kb 
Coating of 
the particle 





























Low  Low  High  Low  Low  High 
 
1.5.3 Lentiviral vectors 
Lentiviruses  belong  to  the  Retroviridae  family  that  consists  of  single  stranded  RNA 






Foamy  Virus316,317,  Human  Immunodeficiency  Virus  (HIV)318,319,  Simian 
Immunodeficiency  Virus  (SIV)320,  Bovine  Immunodeficiency  Virus  (BIV)321,  Feline 
Immunodeficiency  Virus  (FIV)322,  Equine  Infectious  Anemia  Virus  (EIAV)323,  Murine 
Leukemia  Virus  (MLV)324,325,  Bovine  Leukemia  Virus  (BLV)326,  Rous  Sarcoma  Virus 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is  initiated by the enhancer‐promoter  located  in  the 5’ U3 region,  the viral genomic 
RNA starts with R, and is followed by U5, the primer binding site (PBS) for initiation of 
reverse  transcription,  the  major  splice  donor  (SD)  and  the  packaging  and  RNA 
dimerization signal (ψ), all located upstream of the translational start codon of gag/pol 
(encoding  structural  and  replication  proteins).  Downstream  of  the  gag/pol  coding 
region  the  env  (encoding  the  viral  envelope  glycoprotein)  reading  frame  is  found, 
whose expression is enabled by a splice acceptor  located in pol. The 3’ untranslated 
region  of  the  RNA  contains  the  polypurine  tract  (PPT),  and  the  3’  incomplete  LTR 
consisting of  the 3’ U3, and the 3’ R region. The  latter contains  the polyadenylation 
signal and is thus followed by a polyA tail. Since the viral RNA carries a 5’ cap and a 3’ 
pA  tail,  it  resembles  a  cellular  mRNA.  It  is  only  due  to  the  unique  mechanism  of 
reverse transcription that the complete LTRs are restored prior to  integration of the 
virus into the host cell genome330.  
Figure  4:  Genome  structure  of  a  gammaretrovirus: MLV.  Indicated  are  the  5’  and  3’  long  terminal 
repeat (LTR; open boxes) regions comprising U3, R and U5, as well as open reading frames (filled boxes) 








capsid  breaks  open  and with  the  help  of  the  proteins  packaged  inside  the  particle 






host  cell  chromatin,  lentiviruses  can  interact  with  cytoplasmic  carriers  and  actively 
migrate  into  the  nucleus  without  the  need  for  nuclear  membrane  disintegration. 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In  the  second phase of  the  life  cycle,  viral  genes  that  are now part of  the host  cell 
genome  are  transcribed  (6)  and  viral  proteins  are  expressed  using  the  cellular 
machinery (7). Once all the viral proteins are expressed, assembly and budding starts 
on  the  host  cell  membrane  (8)  and  new  virus  particles  start  budding  off  the  cell, 
followed by maturation of the virus particle (9) 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In  the  case  of  lentiviral  vectors,  the  second phase  of  the life  cycle  is  not  desirable. 
Instead  of  expressing  viral  genes  and  packaging  new  virus  particles,  the  expected 
result is the expression of the therapeutic gene. Therefore, in order to turn a virus into 
a  viral  vector,  all  viral  elements  inside  the  viral  genome  are  removed  and  replaced 
with the GOI.  In  this case,  the virus has no capacity  to produce more virus particles 




7. Basically,  the whole viral genome  is  first cloned  into a plasmid  (a). Secondly,  two 
new plasmids are derived  from this one  (b).  In  the  first plasmid  (called  the  transfer 
plasmid), viral genes are replaced with the gene of interest and in the second plasmid, 
the  viral  genes  are  present  but  the  packaging  signal  is  removed. When  these  two 
plasmids  are  co‐transfected  into  a  cell  line,  the  viral  genes  are  expressed from  the 
second  plasmid  but  the  viral  RNA  coming  from  the  second  plasmid  cannot  be 
packaged due to the lack of a packaging signal. Instead, the viral proteins in the cell  
Figure 7: From virus to viral vector 
can be used  to package  the RNA  coming  from  the  first  plasmid,  resulting  in  a  virus 




different  envelope  proteins  for  packaging  the  same  viral  genome  by  changing  the 
plasmid coding for the env gene. Also, the removal of LTRs provides extra security by 
decreasing  sequence  similarity  between  the  transfer  plasmid  and  the  packaging 
plasmids, therefore decreasing the risk of recombination between the plasmids during 




to study different aspects of  the viral  life cycle  in  the early 1990s331‐335, but  the key 
breakthrough came with the construction of vectors that, in contrast to MLV‐derived 
ones,  were  capable  of  transducing  non‐dividing  neurons  when  injected  into  rat 




by  two  wild  type  LTRs  and  bearing  sequences  required  for  viral  RNA  export  in 
producing  cells  (the  Rev‐Responsive  Element,  RRE),  genome  packaging  and  reverse 






of gene transfer, as  for example  the use of post  transcriptional  regulatory elements 
that  enhance  the  transgene  transcriptional  expression,  or  the  use  of  heterologous 
polyadenylation enhancer elements, as those derived from simian virus 40 (SV40) or 
β‐globin, or the use of different internal promoters to express a particular GOI. 





stomatitis  virus  (VSV‐G)  enables  highly  efficient  packaging  of  viral  particles  and 
broadens  the  tropism  of  the  viral  vector  as  it  uses  common  membrane  lipids  as 
receptors338.  Aside  from  VSV‐G,  for  genetic  modification  of  human  hematopoietic 
cells,  pseudotyping  lentiviral  vectors  with  the  envelope  glycoproteins  of  following 
viruses  have  been  reported  to  provide  an  efficient  approach:  Venezuelan  equine 
encephalitis  virus  (VEEV)339,  Measles  virus  (MV)340,  Feline  endogenous  virus 
(RD114)341‐344,  Human  T‐cell  leukemia  virus  type‐1  (HTLV‐1)345  and  Gibbon  ape 
leukemia virus (GALV)344. 





mutagenesis346,347.  A  single  random  insertion  of  a  retroviral  copy  may  induce 
oncogene  activation  and  subsequent  malignant  transformation  of  the  genetically 
modified cells348. Lentiviral vectors also have the ability to insert several vector copies 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into  the  target  cells349, which  leads  to a  similar prediction  for  the  risk of  insertional 
mutagenesis350,351. However, one could argue about whether insertional mutagenesis 
is  a  justifiable  concern  in  the  context  of  genetic  modification  of  terminally 
differentiated  cells  as  compared  to  stem  cells.  It  is  highly  likely  that  terminally 
differentiated cells will not be able to sustain tumor growth due to their finite lifespan. 
As the theory of cancer stem cells352 gains momentum, confirmed by observations of 
tumor  sustainability  through  endeavors  of  a  small  stem  cell‐like  population, 
modification of terminally differentiated cells seems safer compared to modification 
of  stem  cells.  It  could  be  argued  that  although  one  single  hit  could  trigger 
tumorigenesis at the stem cell level, it would take many more hits in a “destined‐to‐
die” terminally differentiated cell. Moreover, current evidence suggests that mature T 
cells  are  resistant  to  oncogene  transformation353.  Although  promising,  such 
conclusions  should  be  taken  with  caution  and  it  should  be  kept  in  mind  that 
malignancies of  terminally differentiated  cells –such as NK or T  cell  lymphomas‐ do 
exist. 
The  possibility  for  genetic  rearrangement  should  be  significantly  lower  in  fully 
committed  differentiated  effector  cells.  Nonetheless,  the  risk  of  insertional 
mutagenesis  associated  with  the  use  of  integrating  vectors  needs  to  be  further 
investigated  and  the  need  for  development  of  vectors  with  safe  integration  sites, 
increased  transduction  efficacy  at  low  multiplicity‐of‐infection  (MOI)  or  stable 
episomal gene expression is essential. As a consequence, the choice of an appropriate 
vector  for  gene  delivery  as  well  as  the  targeted  delivery  and  expression  of  the 
transgene are important issues in gene therapy settings.  
1.5.4 Genetic modification of NK cells 
Gene  transfer  into  NK  cells  may  open  new  possibilities  for  the  immunotherapy  of 
cancer in both autologous and allogeneic settings. The use of genetically modified NK 
cells  that  have  been  redirected  to  tumor  targets  via  the  introduction  of  either 




electroporation355‐357  or  nucleofection358  applications  are  under  significant 
improvement,  stable  transduction  using  retroviral359‐365  or  lentiviral366‐372  vectors 
present a greater advantage in terms of long‐term effects and sustainability. 
Liu et al. have reported transfection of the CD18 gene into a clone of the NK cell line 
YT‐1  that  lacks  functional  CD18  expression.  They  have  demonstrated  that  upon 






activation  of  other  immune  cell  populations.  More  specifically,  activated  T  cells 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increase the chance of GvHD379, while the stimulation of immunosuppressive Treg cells 
is  suboptimal  for  cancer  patients380.    In  settings  where  IL‐2  is  given  primarily  to 
enhance  NK  activity,  administration  in  a  form  that  stimulates  NK  cells,  without 
unwanted side effects, would be ideal. There have been various reports on IL‐2 gene 
delivery via  retroviral  transduction363 or particle mediated381  transfection to  the  IL‐2 
dependent NK cell line NK‐92. Stable transduction of the IL‐2 gene increased cytotoxic 
activity against tumor cell lines in vitro. Such a modification enabled the secretion of 
IL‐2  by  the NK92  cells  and  saved  the  cells  from  the dependency on  exogenous  IL‐2 
supplementation.  Moreover,  the  IL‐2  transduced  cells  showed  greater  in  vivo 
antitumor activity in mice363. Similarly, Miller et al. have reported that IL‐2 transduced 
mouse NK cells sustained proliferation in the absence of exogenously supplied IL‐2382. 
However,  the  expression  of  IL‐2  in  a  secreted  manner  by  NK  cells  may  affect 
neighboring cells or have the potential to cause a systemic IL‐2 effect in patients. This 
risk  prompted  us  to  continue  investigation  to  seek  alternative  approaches  for  IL‐2 
delivery  retained  in  NK  cells  in  a  controlled  and  localized  manner.  Our  group  has 
constructed an endoplasmic reticulum‐retained IL‐2 gene that is not secreted but still 
confines  autocrine  growth  stimulation  to  NK‐92  cells365.  Such  an  approach may  be 
useful for future applications where secretion of high levels of IL‐2 by the adoptively 
transferred NK cells might cause side effects. 
Another  approach  to  genetic modification  of  NK  cells  for  cancer  immunotherapy  is 
retargeting  of  the  NK  cells  to  tumor  cells  via  the  expression  of  chimeric  antigen 
specific  receptors.  This  is  generally  done  by  using  a  single‐chain  variable  fragment 
receptor  specific  for  a  certain  tumor‐associated  antigen  fused  to  the  intracellular 
portion  of  the  signalling  molecule  CD3ζ.  Such  receptors  have  been  used  by  many 
different  groups  and  have  proven  to  be  efficiently  working  in  NK  cells.  Chimeric 
receptors  against  CEA383,  CD33384  and  Her2/neu364,385,386,  have  been  successfully 
delivered  to  NK  cell  lines  and  were  shown  to  increase  antigen  specific  cytotoxic 
activity of NK cells both in vitro and in vivo.  
These improvements have rapidly been translated to settings of primary NK cells and 
experimental  models.  Pegram  et  al.  have  gene  modified  primary  mouse  cells  to 
express a chimeric receptor against Her2/neu and observed that the adoptive transfer 
of  these  cells  to  mice  bearing  Her2+  tumors  inhibits  tumor  progression  in  vivo387. 
Likewise,  Kruschinski  et  al.  have modified  primary  NK  cells  from  human  donors  to 
express  a  chimeric  receptor  against  Her2/neu  and  observed  high  level  of  cytotoxic 
activity  against  Her2+  cell  lines  both  in  vitro  and  in  xenograft  models  with  RAG2‐/‐ 
mice388. Moreover,  Imai et al. have successfully demonstrated  that NK cells  from B‐
lineage ALL patients genetically modified to express a chimeric receptor against CD19 
efficiently kill autologous leukemic cells in vitro362. Taken together, these data indicate 




critical  viral  elements  such  as  envelopes  or  promoters  and  the  process  of  viral 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infection. Previous reports have included various approaches such as the use of feeder 
cells362,371,388,  multiple  rounds  of  transductions359,369,371  or  co‐culture  with  virus 
producing cells363 in an attempt to ensure efficient culture and genetic modification of 





While high resistance against viral  infections serves  the evolutionary purpose of  the 
NK cell, it presents a big disadvantage when it comes to genetic modification via the 
use  of  viral  vectors.  As  with  wild‐type  viruses,  intracellular  recognition  of  viral 
components  by  pattern  recognition  receptors  is  a  possible  mechanism  of  cellular 
response  against  viral  vectors391,392.  Although  the  literature  is  scarce  regarding  the 
activation  of  such  responses  against  lentiviral  vectors,  it  has  been  shown  that  an 
innate immune response against the vector can be generated by plasmacytoid DCs393. 
Such  responses against  lentiviral  vectors have also been documented during in  vivo 
studies after systemic administration of the vector, resulting type 1 IFN responses and 
vector clearance394. In PAPER III, we aimed at looking into whether these mechanisms 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2 AIMS OF THIS THESIS 
The  long‐term  goal  of  this  research  is  to  use  ex  vivo  expanded  and/or  genetically 
modified human NK cells with high anti‐tumor activity in adoptive immunotherapy of 
cancer.  In  order  to  reach  this  goal,  we  have  aimed  at  optimizing  protocols  for  the 
expansion and genetic modification of NK cells. More specifically, we have focused on: 
 
o Investigation  of  the  feasibility  of  expanding  NK  cells  with  autologous  anti‐
tumor  activity  from  PBMCs  of  patients  with multiple  myeloma  using  GMP‐
grade components  (PAPER I) 
o Optimization and validation of a  clinical grade,  large‐scale NK cell expansion 
process in an automated bioreactor (PAPER II) 
o Efficient lentiviral genetic modification of NK cells (PAPER III) 








final  concentration  of  10  ng/ml.    The  cultures  were  then  replenished  with  fresh 
medium  containing  500  U/ml  IL‐2  but  not  OKT3,  every  other  day  throughout  the 
culture period.  Total  cell  numbers were  assessed by  staining  cells with  Trypan blue 
dye  on  days  0,  5–6,  9–10,  14–15,  and  20  of  culture.  Absolute  cell  counts  were 
calculated  by  multiplying  the  total  number  of  cells  by  the  percentage  of  specific 
subsets determined by flow cytometry. To prevent contact  inhibition of cell growth, 
the  cells were  transferred  to bigger  flasks when necessary.  The  final products were 





VuelifeTM  (American  Fluoroseal  Corporation,  MD,  USA)  is  a  sterile  cell  culture  bag 
made  of  fluorinated  ethylene‐propylene  that  is  claimed  to  be  biologically, 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3.1.3 Expansion of NK cells in bioreactor (PAPER II) 
The  Wave  Bioreactor  is  a  cell  culture  system  where  the  cells  are  grown  inside  a 
temperature  and  CO2  controlled  disposable,  sterile  bag  that  is  placed  on  a  rocking 









donors  and MM patients were  obtained  and  the  cultures were  initiated  directly  in 
bioreactors from day 0. The conditions for the bioreactor were as follows at all times: 
Temperature 37°C, CO2: 5%, Airflow: 0.1, Rocking rate: 6/min, Rocking angle: 6°. The 
cells were  sampled  and  counted  every  other  day  and  no  further  feeding was  done 
until the cell density reached 3x106 cells/ml. From then on, the culture was fed with 
300 ml of medium per day. When the cells  reached a density of 7x106 cells/ml,  the 










The  cytotoxic  capacities  of NK  cells were  evaluated  in  vitro with  a  standard  4‐hour 
51Cr‐release assay against K562 cells. In short, K562 target cells were labeled with 100 
μCi  of  51Cr  for  1  hour  at  37°C,  washed  twice  with  PBS,  and  resuspended  in  RPMI 
medium. A total of 3x104 target cells in 100 μl RPMI medium was placed in triplicates 
into V‐bottomed 96‐well plates and incubated for 4 hours with 100 μl of effector cells 
at appropriate concentrations to obtain effector:target  (E:T)  ratios  from 1:3 to 10:1. 
Aliquots  of  supernatants  were  counted  using  a  Packard  Cobra  Auto‐Gamma  5000 
Series Counting System. The percentage specific 51Cr release was calculated according 
to  the  formula:  percent  specific  release=  [(experimental  release  ‐spontaneous 
release)/(maximum release‐spontaneous release)]x100. 
3.2.2 Flow cytometry‐based cytotoxicity assay (PAPER I) 
Target  cells,  were  labeled  with  TFL4  reagent  from  the  CytoToxiLux‐PLUS  kit 
(OncoImmunin  Inc.,  Gaithersburg,  MD,  USA)  according  to  the  manufacturer’s 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instructions. In all flow cytometry based cytotoxicity assays, 5x104 labeled target cells 
were  placed  in  tubes  together  with  different  amounts  of  effector  cells  to  obtain 
effector:target ratios from 1:3 to 10:1 in a final volume of 300 µl RPMI medium and 
incubated at 37°C  for 4 h. The cells were  then washed once with PBS. Following Fc 
receptor  blockade  with  IgG  (1  µg/105  cells)  on  ice  for  20  min  to  avoid  antibody‐
dependent cellular cytotoxicity, the cells were incubated with appropriate amounts of 
fluorochrome  conjugated  mAbs  against  CD38  and  CD138  (when  autologous  BM 
samples  were  used  as  targets)  or  CD34  (when  magnetically  separated  CD34+  cells 
were  used  as  targets)  at  4°C  for  30  min.  After  washing  with  PBS,  the  cells  were 
resuspended  in  500  μl  of  PBS  containing  5  μg  7‐aminoactinomycin  D  (7‐AAD; 
Invitrogen, Carlsbad, CA, USA) and incubated in the dark for an additional 15 min at 
4°C before data acquisition by flow cytometry.  
During  analysis  of  the  flow  cytometry  data,  targets  cells  were  isolated  from  the 
effector  cells  by  TFL4  positivity  and  the  percentage  of  live  or  dead  cells  were 
determined  by  using  7‐AAD  staining  on  this  TFL4+  population  as  a  whole  or  with 
further gating on CD38+CD138+ cells (for BM samples as targets) and CD34+ cells (for 
CD34  enriched  samples  as  targets).  Cytotoxicity  was  assessed  according  to  the 





Fluorochrome‐conjugated  anti‐CD107a  mAb  or  the  corresponding  IgG1  isotype 
control was added at the initiation of the assay. After 1 h of coincubation, Monensin 
was added at a 1:100 dilution. Surface staining was done by incubating cells with anti‐




following  protocol:  The  cells  were  washed  once  with  PBS  and  incubated  with 
appropriate  amounts  of  antibody  at  4°C  for  30  min.  The  labeled  cells  were  then 
washed with PBS and fixed in 1‐4% PFA prior to data acquisition. Data acquisition was 
done on FACSCalibur  (BD)  and CyFlow ML  (Partec GmbH, Munster, Germany). Data 
were  analyzed  with  CellQuest  Pro  (BD),  FloMax  (Partec)  and  FlowJo  (TreeStar  Inc.) 
softwares.  
In  detailed  phenotyping  analysis,  for  each  cell  surface  receptor  analyzed,  mean 
fluorescence intensity (MFI) values were calculated for day 0 and day 20 samples. To 
estimate the change in receptor expression between different samples, we calculated 
MFI  ratios  (MFIday20/MFIday0  or MFIbioreactor/MFIflask)  for  each  receptor. When  the MFI 
for  a  sample  was  higher  than  another,  the  MFI  ratio  was  higher  than  1,  which 








(1C6/CXCR3),  CD226  (DX11),  NKB1  (DX9),  LFA‐1  (HI111),  CD62L  (DREG56),  CD69 
(FN50) and CD138  (MI15) purchased  from BD Biosciences,  San  Jose, CA, USA; CD48 
(MEM102)  from  Biosource  AB,  Stockholm,  Sweden;  CD158B1/B2,j  (GL183), 
CD244(2B4) (C1.7), NKG2D (ON71), NKp30 (Z25), NKp44 (Z231), NKp46 (BAB281), LIR‐
1  (HP‐F1), Valpha24  (C15), Vbeta11  (C21)  from Beckman Coulter  Inc.,  Fullerton, CA, 
USA; NKG2A  (131411),  NKG2C  (134591),  KIR2DL1  (143211),  KIR2DL3  (180701)  from 
R&D Systems, Minneapolis, MN, USA.  
PAPER II:  
CD11a  (HI111),  CD3  (UCHT‐1),  CD7  (M‐T701),  CD14  (MOP9),  CD16  (3G8),  CD19 
(HIB19),  CD25  (M‐A251),  CD27  (M‐T271),  CD56  (B159),  CD57  (NK‐1),  CD226  (DX11), 
NKB1 (DX9) and CD62L (DREG56) purchased from BD Biosciences, San Jose, CA, USA; 
CD244(2B4)  (C1.7),  NKG2D  (ON71),  NKp30  (Z25),  NKp44  (Z231),  NKp46  (BAB281), 
from  Beckman  Coulter  Inc.,  Fullerton,  CA,  USA;  NKG2A  (131411),  NKG2C  (134591), 





8.1), CD16  (3G8), CD226  (DNAM‐1)  (DX11), CD25  (M‐A251), NKG2D  (1D11)  from BD 
Biosciences;  NKG2A  (Z199),  CD158a,h  (KIR2DL1/S1)  (EB6B),  CD158b1/b2,j 
(KIR2DL2/3/S2)  (GL183),  NKp30  (Z25),  NKp46  (BAB281),  CD244  (2B4)  (C1.7)  from 
Beckmann  Coulter;  CD158e1/e2  (KIR3DL1/S1)  (DX9),  CD62L  (DREG‐56)  from 
BioLegend and CD45 (HI30) from Invitrogen. 
3.5 PRODUCTION OF LENTIVIRAL VECTORS 








viral  titers  by  transduction  of  293FT  cells  with  serially  diluted  amounts  of  virus 
supernatant. Figure 9 illustrates the key features of the LeGO‐G2 vector. 




cPPT,  central  polypurine  tract;  LoxP,  loxp  sites  to  allow  for  excision  after  introduction  of  CRE 







temperature.  After  centrifugation,  without  removing  viral  supernatants,  the  plates 
were incubated at 37°C, 5% CO2 for 4‐6 hours. At the end of the incubation, a second 
centrifugation at 1000xg for 1 hour at room temperature was carried out, after which 
the  supernatants  were  removed  from  the  wells  and  1  ml  of  fresh  NK  cell  growth 
medium  per well  was  added.  The  cells  were maintained  in  this medium with  daily 










Following  our  results  that  showed  the  potent  anti‐myeloma  effect  of  adoptively 
transferred  IL‐2  activated  NK  cells  in  an  animal  model175,  we  have  decided  to 
investigate  the  feasibility  of  a  similar  approach  in  the  human  setting.  Since  results 
from  animal  studies  have  indicated  a  dose‐dependent  effect  of  NK  cells  for  MM 
immunotherapy, we have primarily  investigated whether NK cells from MM patients 
can be expanded ex vivo and whether the expansion and activation process reverses 
the  phenotypic  and  functional  defects  in  this  lymphocyte  population, making  them 
efficient killers of autologous tumor cells. 




on  average  1625‐fold  (range:  502‐2658).  Because  the  expansion  of  NK  cells  was 
relatively  higher  than  that  of  the  other  cell  types,  NK  cells  dominated  the  culture 
towards the end of  the  incubation,  reaching on average 65% of  the cells by day 20. 





As  expected,  cytotoxicity  by  the  expanded  cells  against  the  standard NK  cell  target 
K562 was markedly elevated compared to effector cells from day 5 or day 0 cultures. 
Yet,  the  real  challenge  in  this  case  was  whether  the  expanded  cells  showed  any 
cytotoxic  activity  against  autologous  MM  cells.  Our  results  revealed  that  day  20 
expanded  cells were  highly  cytotoxic  against  autologous MM  cells whereas  neither 
day 0 nor day 5 cells showed more than low levels of cytotoxicity (Figure 11).  
In  an  attempt  to  identify  the  phenotypic  changes  associated  with  this  cytotoxic 
activity, we also phenotyped the expanded NK cell population to compare the starting 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material with that at day 20 of expansion. Since a balance of activating and inhibitory 
signals regulates NK cell function29, optimal NK cell effector function is expected when 
the  expression  of  activating  NK  cell  receptors  is  adequate  and  not  suppressed  by 
inhibitory signals. Our results show that, following ex vivo expansion, NK cells undergo 
major  phenotypic  changes  and  upregulate  the  expression  of  many  activating 
receptors (2B4, CD8, CD16, CD27, CD226, NKG2C, NKG2D, NKp30, NKp44 and NKp46).  
Figure 11: Cytotoxic activity of expanded cells against MM and non‐MM cells of the bone marrow 
To  determine  the  relative  contributions  of  the  foregoing  activating  receptors,  we 
performed  cytotoxicity  experiments  after  blocking  receptors  with  antibodies  either 
alone  or  in  different  combinations. We  observed  no  specific  association  of  NK  cell 
cytotoxicity with a single receptor but, rather, effects were likely mediated by several 
receptors. This outcome indicates that several activating receptors may contribute to 





Our  data  also  indicate  that  the  recognition  of  autologous  MM  cells  by  NK  cells 
expanded  ex  vivo  involves  a  certain  degree  of  specificity  since  we  observed  no 
cytotoxicity  against  non‐MM  cells  in  the  BM  or  towards  magnetically  separated 
autologous CD34+ cells from BM and autologous PHA‐blasts.  
Alongside  research  to  unravel  the  mechanisms  responsible  for  the  phenomena 
reported here,  the  feasibility of using autologous NK  cells  expanded ex  vivo  for  the 
management of MM patients is worthy of further exploration in order to verify their 
clinical potential. In this context, we propose that expanded NK cells can be used as a 
support  to  ASCT  for  preemptive  treatment  of  relapse  and  better  eradication  of 
malignant  cells  in  MM  patients.  Since  our  results  convincingly  demonstrated  that 
expanded  autologous  NK  cells  could  be  a  potentially  effective  approach  for  MM 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immunotherapy,  we  decided  to  initiate  a  clinical  study  in  order  to  investigate  this 





an  automated  bioreactor)  in  comparison  to  conventional  cell  culture  flasks  using 




of  feeder  cell  lines258,261  have  been  widely  used  for  NK  cell  expansion  in  previous 
reports. In this study, we did not utilize any feeder cells or separation steps but rather 





bioreactor when  sufficient  amount  of  cells was  reached.  The NK  expansion  in  bags 
appeared  impressive when compared  to  flask especially  in  three out of  five donors. 
However, we observed that expansion in bags might result in a lower NK cell purity in 




clarify  if  the  NK  cells  in  the  final  products  of  different  systems  retain  the  same 
activation  status  and  show  comparable  cytotoxicity,  we  evaluated  the  cytotoxic 
activity  of  the  final  products  against  the  K562  cell  and  observed  no  significant 










cells  reached  was  sufficient  to  facilitate  a  trial  for  clinical  testing.  Moreover,  we 
observed  that when expansion was  initiated  in  bioreactors  from  the beginning,  the 
cytotoxic activity of the final product against K562 cells was remarkably higher when 
compared to the final product of flask expansions in 3 out of 4 donors. 




has  revealed  that  CD132,  CD25,  CD57  and  NKG2C  expression  levels  were  inversely 
correlated with the extent of degranulation while expression levels of NKp30, NKp44 
and  NKp46  were  directly  correlated.  Observing  a  reverse  correlation  with  the 
expression  of  the  activating  NK  cell  receptor  NKG2C  is  unusual  but  has  very  little 
meaning in this case, as the target K562 cells are known to lack the expression of its 
ligand,  HLA‐E400.  Statistical  analysis  of  receptors  correlating  with  NK  cell  response 
revealed  that NKp44 both correlates positively with  response, and  is expressed at a 





level  of  expression  in  bioreactor  products,  and  values  below  1  indicate  lower  level  of  expression  in 
bioreactor products. 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This  can,  at  least  in  part,  explain  the  observation  of  high  cytotoxic  capacity  of  the 
bioreactor  products.  Unlike  the  other  NCRs,  NKp4436  is  expressed  exclusively  on 
activated NK cells and is upregulated after in vitro IL‐2 stimulation401. Therefore, in this 
case, it might be presenting as a surrogate marker of how well the IL‐2 in the culture is 
being used and what  the extent of activation  in  the NK cell population  is. Thus,  the 
elevated  expression  of  NKp44  provides  a  functional  significance  to  the  expansion 




may  be  used  for  the  treatment  of  patients with malignancies  and  clinical  trials will 
help to shape the future role of NK cells in cancer immunotherapy. Having optimized 
the procedure  for NK  cell  expansion  in  a  closed‐automated bioreactor using  clinical 




Since we were not able  to pinpoint  the exact nature of  the  interaction between NK 
cells  and  MM  cells  in  PAPER  I,  we  decided  to  investigate  these  interactions  by 
genetically  modifying  NK  cells.  Current  approaches  to  characterize  NK‐tumor 
interactions rely mainly on surface phenotyping of tumor cells for a limited number of 
identified NK cell ligands and cytotoxicity assays in the presence of blocking antibodies 
against  receptors  on  the  NK  cell  surface.  Both  approaches,  although  widely  used, 
present serious defects in detecting targets that could be of therapeutic significance. 
Phenotyping  the  identified  ligands often results  in detection of one or more NK cell 
ligand on the tumor targets, but the main restriction is the lack of knowledge about 
ligands and availability of specific antibodies for those. Even for the identified ligands 
that  do  have  antibodies  available,  the  mere  detection  of  ligand  expression  on  the 
target cell surface provides very limited information about the functional significance 
of a possible  interaction  through  that  ligand.  In  that  sense, measuring  the cytotoxic 
activity  of  the NK  cell  after  blocking  of  the  activating  receptor  that will  engage  the 
detected ligand proves to be more informative. However, this method has an inherent 
assumption  that  the NK  cell  already  expresses  the  receptor  in  question.  Yet,  it  has 
been  repetitively  observed  by  many  researchers  that  malignant  cells  induce 
phenotypic  aberrations  on  NK  cells63,402,403.  If  the  tumor  has  already  succeeded  to 
modify  the phenotype of  the patient’s NK cells and caused the downregulation of a 
certain receptor, there’s no information that could be gained by blocking a receptor 
which  is not  there. Therefore, genetic modification provides  information that would 
not  be  possible  to  reach  otherwise.  For  this  purpose,  we  decided  to  optimize  a 
lentiviral transduction protocol for primary human natural killer cells404,405. 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(red),  a  balance  of  activating  and  inhibitory  signals  prevails  (A).  It  is  possible  to 
overcome  this  balance  via  genetic  modification  by  either  upregulating  activating 
receptors  (orange) on the NK cell surface (B) or downregulating  inhibitory receptors 
(green) in order to abolish the inhibitory signalling (C). Such an approach can be used 
for  gaining  a  basic  understanding  of  the  receptors  involved  in  target  cell  killing  or 






against a virus  infection390. The  intracellular anti‐viral  response of NK cells has been 
studied thoroughly in wild‐type virus infections406 but it has been mostly overlooked 
from  a  gene  therapy  point‐of‐view whether  these  responses  are  still  active  against 
viral vectors and have a significant effect in the resistance of NK cells to efficient viral 
transduction.  
For  this  purpose, we  primarily  tried  to  establish  a  firm  starting  point  by  evaluating 
different  cytokine  stimulations  prior  to  viral  transduction.  Among  the  cytokines we 
have tested were IL‐2 and IL‐15, which are commonly used for culture and activation 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Furthermore,  we  have  hypothesized  that  inhibition  of  innate  immune  receptor 
signaling  would  contribute  enhanced  transduction  efficiency.  It  is  well  known  that 
TLRs and RLRs play a major  role  in detection of  viral  infections and  induction of  an 
anti‐viral  state407,408. Many wild‐type  viruses  have  developed  elaborate  schemes  to 
avoid detection by these receptors and increase their virulence409. In the case of viral 
vectors,  the  removal  of  various  viral  genes  that  counteract  host  responses  but  are 
dispensable  for  vector  production  is  often  preferred  due  to  safety  and  practicality 
considerations.  Inevitably,  this  would  render  viral  vectors  more  prone  to  inducing 
strong innate responses upon target cell infection391. We have hypothesized that TLR 
or  RLR  mediated  detection  of  viral  vector  components  might  activate  an  anti‐viral 
response  in NK  cells,  negatively  effecting  the efficiency of  lentiviral  transduction.  In 
order to test this hypothesis, we have attempted to use small molecule inhibitors of 
TLR and RLR signaling preceding lentiviral transduction.  
We  have  discovered  that  the  use  of  BX795  at  2µM  concentration  dramatically 
increased transduction efficiency. BX795 is an inhibitor of TBK1/IKKε complex that acts 




viral defense mechanisms  including one or more of  the  receptors RIG‐I, MDA‐5 and 
TLR3 are activated and contribute significantly to the resistance of NK cells to lentiviral 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genetic  modification.  Testing  different  concentrations  of  BX795  showed  that  the 
inhibitor has a dose‐dependent effect on increasing genetic modification efficiency in 
NK cells  (Figure 16). Although a  significant effect  is  seen at 2µM concentration,  this 
effect increases even more up to 6µM after which it seems to stabilize.  
 
Figure  16.  Dose  response 
and of BX795 treatment. NK 
cells stimulated with  IL‐2/IL‐
21  for  two  days  were 











along  with  IL‐2/IL‐21  stimulation  presents  any  functional  or  phenotypic  concerns 
regarding NK cell cytotoxic capacity. We have not observed any alteration in cellular 
cytotoxicity  after  treatment  with  BX795  alone  or  transduction  in  the  presence  of 
BX795. 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5 CONCLUDING REMARKS AND FUTURE PERSPECTIVES 
The  work  presented  in  this  thesis  is  dedicated  to  bringing  NK  cell‐based 
immunotherapeutic approaches into the clinic. We have discovered that long‐term ex 
vivo  expansion  and  activation  of  autologous  NK  cells  from  MM  patients  provides 
significantly superior cytotoxic activity against autologous tumor cells when compared 
to short‐term activated autologous NK cells. Having optimized the procedure for NK 
cell  expansion  in a  closed‐automated bioreactor using  clinical  grade GMP‐compliant 
components, we have finished all the preclinical requirements and got approval from 
Swedish Medicinal Products agency and  the ethical  committees  to  initiate a  first‐in‐
man phase I/II clinical trial.   
A phase I/II clinical trial was designed to evaluate primarily safety and, to some extent, 




o To  determine  the  safety  of  ex  vivo  expanded  NK  cell  infusions  for  the 
management of MM relapse after ASCT. 
o To evaluate the survival and functional capabilities of the infused product. 
o To  determine  the  efficacy  of  these  cells  to  restore  clinical,  cytogenetic  and 
molecular remission in patients with MM.  
Figure 17: Design of the clinical protocol for expanded NK cell therapy in MM patients 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We intend to use PBMCs and tumor samples from patients in a medium‐throughput 
assay  where  the  outcome  of  each  genetic  modification  will  be  assessed.  Basically, 
PBMCs will be used to enrich NK cells by magnetic cell separation, which will then be 
cultured  in  specialized  media  with  minimal  amount  of  cytokines.  Next,  the 
transduction  of NK  cells will  be  carried  out  by  lentiviral  vectors  encoding  genes  for 
activating  receptors  or  shRNAs  against  inhibitory  receptors  along  with  GFP  or 
tdTomato. After transduction, the NK cells will be used in degranulation assays, where 
the  response against  target  cells will be measured. Besides  the  regular  control    (NK 
cells  transduced with  a  vector  expressing only GFP) we will  also be able  to use  the 
non‐transduced  cells  for  each  transduction  as  an  internal  control  and  compare  the 







background degranulation when  there  are no  targets present. For  each patient, NK 
cells  will  be  transduced  with  various  different  activating  receptors  or  shRNAs  and 
response against autologous tumor cells as well as autologous PBMCs will be assessed 
and  analyzed  side‐by‐side.  This  will  provide  information  regarding  the  role  of  each 
receptor in the interaction with target cells and whether that role is tumor‐specific or 
not.  Genetic  modification  strategies  and  viral  vectors  used  in  this  study  will  also 
enable  upregulation  of  a  pair  of  receptors  at  a  time  in  case  certain  synergistic 
interactions between those receptors are to be studied. 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the patient’s autologous NK cells and tumor cells. It will also provide patient‐specific 
data regarding the significance of each receptor in a possible NK cell‐based immuno‐
gene  therapy  setting.  As  both  the  character  of  the  tumor  cell  population  and 
phenotypic  status  of NK  cells  differ  from  patient  to  patient,  such  an  approach will 
prove  to  be  instrumental  in  developing  patient‐tailored  cancer  immunotherapy 
approaches based on NK cells by providing therapeutically relevant targets. Analysis of 
effects  on  interactions with  non‐tumor  cell  populations will  increase  this  relevance 
even  further by means of controlling  the specificity of  identified targets. Finally,  the 
results will establish a firm background of knowledge for facilitation of NK cell genetic 
modification processes for possible applications in cancer immunotherapy. 
There  is  a  need  for  novel  therapies  against  hematological  malignancies  and  solid 




hematological malignancies  as well as  solid  tumors.  The methods  presented  in  this 
thesis  comprise  expansion  of  NK  cells  for  clinical  purposes  and  preclinical 
development of NK cell genetic modification processes. The next step in this road is to 















changed me.  I don’t know if  I managed to fit  in smoothly  (most probably not) and  I 
don’t  yet  know  if  I  like  this new me. One  thing  I  know  for  sure  is  that most of  you 
people met me at a very strange time  in my  life. I would  like to express my sincere 
gratitude to all of you who have helped and supported me through this time. It would 
not be possible without you: 
Evren  Alici,  my main  supervisor,  for  all  the  things  you  taught  me,  for  your  never‐






Hareth  Nahi,  my  co‐supervisor,  for  sharing  your  myeloma  expertise,  for  your 
unconditional support and for your patience with me. 
Hans‐Gustaf Ljunggren, my co‐supervisor, for your support and advice in all issues, for 
inspiring  me  with  the  impressive  way  you  conduct  scientific  results  during  the 
preparation of the first paper. 
Adnane  Achour,  my  co‐supervisor,  for  all  the  times  you  have  shown  interest  and 
appreciation for the work I have been doing. To be honest, it felt really good. 




say  “it would not be possible without you” but when  I  talk about  the  two of you,  I 
can’t 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effort). If I had given 
you an “öre”  for every NK cell  you  separated  for 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a 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